RAS oncogene mutations are found in about 50% of CRC tumours with KRAS being the dominant and NRAS less frequent, while BRAF mutations are reported in 5–10% of tumours, with up to 21% reported in cohorts of patients with unresectable metastatic CRC (mCRC) [2, 3]. Here, KRAS is linked to neoplasm.